United Therapeutics Corporation
UTHR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $15,948 | $10,291 | $12,653 | $9,702 |
| - Cash | $1,697 | $1,208 | $961 | $895 |
| + Debt | $300 | $700 | $800 | $800 |
| Enterprise Value | $14,551 | $9,783 | $12,492 | $9,607 |
| Revenue | $2,877 | $2,328 | $1,936 | $1,686 |
| % Growth | 23.6% | 20.2% | 14.9% | – |
| Gross Profit | $2,568 | $2,070 | $1,790 | $1,563 |
| % Margin | 89.2% | 88.9% | 92.4% | 92.7% |
| EBITDA | $1,654 | $1,387 | $1,040 | $737 |
| % Margin | 57.5% | 59.6% | 53.7% | 43.7% |
| Net Income | $1,195 | $985 | $727 | $476 |
| % Margin | 41.5% | 42.3% | 37.6% | 28.2% |
| EPS Diluted | 24.64 | 19.81 | 15 | 10.06 |
| % Growth | 24.4% | 32.1% | 49.1% | – |
| Operating Cash Flow | $1,327 | $978 | $803 | $598 |
| Capital Expenditures | -$247 | -$230 | -$139 | -$121 |
| Free Cash Flow | $1,081 | $748 | $664 | $477 |